Can Caregivers Microdose Cannabis Safely for Dementia?

PostedMarch 12, 2026

UpdatedMarch 12, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Microdosing refers to taking very small amounts of cannabis, often below the threshold that produces noticeable psychoactive effects. Some caregivers wonder whether this approach could help manage agitation, anxiety, or sleep issues in people living with dementia without causing confusion or drowsiness.

According to NHS guidance, cannabis-based medicinal products (CBMPs) can only be prescribed by specialist doctors for certain conditions such as epilepsy, multiple sclerosis, or chemotherapy-related nausea, not for dementia. Any use in dementia care remains experimental and should only take place under medical supervision.

What The Research Says

Current evidence does not confirm that microdosing cannabis is safe or effective for dementia. Reviews such as Hermush et al., Frontiers in Medicine (2022) and Outen et al., PMC (2021) report mixed findings from small studies. Some used very low doses of CBD-dominant oils, typically 5–15 mg per day, sometimes with trace amounts of THC (<1 mg). While a few participants showed mild improvement in agitation, most studies found no significant difference compared with placebo.

The Alzheimer’s Society UK warns that dosing in dementia is not standardised, and even small amounts of THC may cause confusion, dizziness, or anxiety (Alzheimer’s Society UK: Cannabis, CBD oil and dementia).

Expert And Regulatory Views

NICE guidance on cannabis-based medicinal products (NG144, 2025) (NICE NG144) states that cannabis should not be prescribed for dementia symptoms outside of approved research settings. No evidence-based microdosing protocol exists for dementia, and caregivers should not administer any unregulated cannabis or CBD products without professional oversight.

Clinical Bottom Line

There is no clinically validated microdosing protocol for cannabis use in dementia care.

CBD-dominant oils at very low doses have been tested but show inconsistent results.

Even small amounts of THC can cause confusion or falls in older adults.

NICE and NHS do not recommend cannabis for dementia outside research.

Caregivers should never administer cannabis without specialist medical supervision.

About AlleviMed

AlleviMed provides educational resources explaining how medical cannabis eligibility is assessed under UK regulations. It helps patients, carers, and clinicians understand the legal frameworks and safety standards governing cannabis-based treatments, supporting informed and responsible decision-making.

Takeaway

Microdosing cannabis for dementia may sound like a gentle approach, but it is not supported by current evidence or clinical guidance. Research remains limited, and even small doses can cause unwanted effects in older adults. NICE and NHS guidelines clearly advise that cannabis should only be used under specialist supervision and within regulated research programmes. Caregivers should never attempt dosing without medical direction.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.